Shattuck Labs to Present at TIGIT Therapies Digital Summit 2020
Shattuck Labs, a clinical-stage biotechnology company, will present at the TIGIT Therapies Digital Summit 2020 on October 26 at 10:00 a.m. EDT. The presentation, titled Using LIGHT to Hotwire TIGIT Blockade, will be led by CEO Taylor Schreiber. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune treatments through its unique ARC® platform. Their leading compound, SL-172154, is currently in a Phase 1 trial, alongside another compound, SL-279252, being tested with Takeda Pharmaceuticals. The presentation will be available for download on their website.
- None.
- None.
DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the TIGIT Therapies Digital Summit 2020 being held virtually October 26 – 27, 2020.
Presentation Details
Presentation Title: Using LIGHT to Hotwire TIGIT Blockade
Date/Time: October 26 at 10:00 a.m. EDT
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Location: www.tigit-therapies.com
The presentation will be available for download on the Events & Presentations section of the Company’s website and also will be available to registered participants of TIGIT Therapies Digital Summit 2020.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint platform, ARC®, simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager platform, GADLEN™, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Durham, North Carolina and Austin, Texas. For more information, please visit: www.ShattuckLabs.com.
